Bristol Myers Squibb, Johnson & Johnson halt major heart-drug trial after disappointing results

Merck to acquire Cidara Therapeutics for $9.2 billion

Diversifying its portfolio to include late-phase antiviral agent

Pfizer completes up to $10 billion acquisition of Metsera

Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape

Daiichi Sankyo launches first-in-human trial of innovative cancer therapy

The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events

Kaiser Permanente’s study highlights power of genetics in preventing heart disease

Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD

Diabetes on the rise: Over 50% of Indians show high blood sugar, reveals report

Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes

Transition Bio and Voyager Therapeutics forge strategic collaboration to target ALS, FTD

The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology

SpyGlass Pharma reports promising clinical trial results for glaucoma therapy

The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance

Carbogen Amcis announces refinancing and enhancement of syndicated credit facilities

The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million

BASF and Beyond Suncare welcome WHO decision to list broad-spectrum sunscreen as “Essential Medicine”

The inclusion of broad-spectrum sunscreen in the WHO EML and EMLc follows an application submitted in November 2024 by the Global Albinism Alliance